Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

Barry Stevenson and his wife Billy started skating about five years ago - just before Barry was diagnosed with prostate cancer. He faced the possibility of being one of the two and a half thousand ...

This past week showed Americans once again that President Donald Trump’s callousness and casual cruelty will never escape the shadow of former President Joe Biden’s decency. Let’s look at each ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...

A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity ...

Dr. Peter O'Donnell presented patient-reported outcomes (PROs) from the phase III KEYNOTE-905/EV-303 trial evaluating perioperative enfortumab vedotin (EV) plus pembrolizumab in cisplatin-ineligible ...